Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...
Nuvation Bio executive departs after key milestones
Nuvation Bio Inc., a pharmaceutical company focused on cancer treatment with a market capitalization of $769 million, announced the departure of Dr. Jerry Wang, CEO of subsidiary AnHeart Therapeutics, ...
Seeking Alpha23d
NUVB Nuvation Bio Inc.
Nuvation Bio Inc. (NUVB) stock price is 2.50 and Nuvation Bio Inc. (NUVB) 10-day simple moving average is 2.62. Nuvation Bio Inc. (NUVB) stock price is 2.50 and Nuvation Bio Inc. (NUVB ...
Business Insider1mon
Buy Rating on Nuvation Bio: Promising Taletrectinib Results and Strong Valuation Support $7 Target
Nuvation Bio (NUVB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock ...
Nuvation Bio begins EAP for taletrectinib in US for advanced ROS1 + NSCLC
Nuvation Bio (NUVB) announced it has initiated an Expanded Access Program or EAP for taletrectinib in the U.S. for the treatment of patients ...
ETF Daily News24d
Assenagon Asset Management S.A. Sells 309,176 Shares of Nuvation Bio Inc. (NYSE:NUVB)
Assenagon Asset Management S.A. lessened its stake in shares of Nuvation Bio Inc. (NYSE:NUVB – Free Report) by 70.5% during the fourth quarter, according to its most recent filing with the ...